TABLE 2.
Sample cell ligand | Syringe ligand | K D (μM) | ΔH (kcal/Mol) |
---|---|---|---|
HpaAA153 | 4‐hydroxybenzoic acid | 28.5 ± 2 | −0.4 ± 0.03 |
TyrRA153 | L‐Phe | Binding a | |
TyrRA153 | L‐Phe + ATP | 193 ± 24 | −0.2 ± 0.01 |
TyrRA153 | L‐Trp | 2681 ± 670 | −1.6 ± 0.5 |
TyrRA153 | L‐Trp + ATP | K D1 = 1638 ± 157; K D2 = 2057 ± 263 | ΔH 1 = −1.8 ± 0.3; ΔH 2 = −7.9 ± 1.7 |
TyrRA153 | ATP | 16.0 ± 0.7 | −22.9 ± 1.5 |
TyrRA153 | L‐Tyr | No binding | |
TyrRA153 + ATP | L‐Tyr + ATP | 6.0 ± 0.2 | −6.8 ± 0.1 |
TyrRA153 | Wild‐type DNA b | 0.193 ± 0.02 | 7.1 ± 0.1 |
TyrRA153 + L‐Tyr + ATP | Wild‐type DNA b + L‐Tyr + ATP | 0.081 ± 0.01 | 8.2 ± 0.2 |
TyrRA153 + L‐Phe | Wild‐type DNA b + L‐Phe | 0.074 ± 0.01 | 6.3 ± 0.1 |
TyrRA153 + L‐Trp | Wild‐type DNA b + L‐Trp | 0.442 ± 0.03 | 3.3 ± 0.1 |
TyrRA153 | Mutant DNA b | No binding |
Note: Data were analysed using the “One binding site model” of the MicroCal version of ORIGIN. The corresponding data are shown in Figures 6, 7, S4 and S8.
No satisfactory curve fit was obtained using models in SEDPHAT (Zhao et al., 2015) or the ORIGIN software (MicroCal). The corresponding titration curves are shown in Figure S8.
26‐mer DNA fragments of the ipdc promoter containing the wild‐type and mutant TyrR box.